Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Scope of the Report:
This report focuses on the Peptide Cancer Vaccine in North America and Europe market, especially in United States, United Kingdom, Canada, Germany, France, Italy and Spain. This report categorizes the market based on manufacturers, countries/Regions, type and application.
Market Segment by Manufacturers, this report covers
TapImmune
BrightPath Biotherapeutics
Ultimovacs
Sellas
Boston Biomedical
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Immatics
Market Segment by Countries, covering
United States
United Kingdom
Canada
Germany
France
Italy
Spain
Market Segment by Type, covers
Market Segment by Applications, can be divided into
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
There are 19 Chapters to deeply display the North America and Europe Peptide Cancer Vaccine market.
Chapter 1, to describe Peptide Cancer Vaccine Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;
Chapter 2, to analyze the manufacturers of Peptide Cancer Vaccine, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the North America and Europe market by countries, covering United States, United Kingdom, Canada, France, Germany, Italy and Spain, with sales, price, revenue and market share of Peptide Cancer Vaccine, for each country, from 2013 to 2018;
Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;
Chapter 7, 8, 9, 10, 11, 12 and 13 to analyze the key countries by manufacturers, Type and Application, covering 7 countries, with sales, revenue and market share by manufacturers, types and applications;
Chapter 14, Peptide Cancer Vaccine market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2018 to 2023;
Chapter 15, to analyze the manufacturing cost, key raw materials and manufacturing process, etc.
Chapter 16, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);
Chapter 17, to describe sales channel, distributors, traders, dealers, etc.
Chapter 18 and 19, to describe the research findings and conclusion, appendix, methodology and data source.
Table of Contents
1 Market Overview
1.1 Peptide Cancer Vaccine Introduction
1.2 Market Analysis by Type
1.3 Market Analysis by Applications
1.3.1 Breast Cancer
1.3.2 Lung Cancer
1.3.3 Melanoma
1.3.4 Prostate Cancer
1.3.5 Others
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2013-2023)
1.4.2 Canada Status and Prospect (2013-2023)
1.4.3 United Kingdom Status and Prospect (2013-2023)
1.4.4 Germany Status and Prospect (2013-2023)
1.4.5 France Status and Prospect (2013-2023)
1.4.6 Italy Status and Prospect (2013-2023)
1.4.7 Spain Status and Prospect (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 TapImmune
2.1.1 Business Overview
2.1.2 Peptide Cancer Vaccine Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 TapImmune Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 BrightPath Biotherapeutics
2.2.1 Business Overview
2.2.2 Peptide Cancer Vaccine Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Ultimovacs
2.3.1 Business Overview
2.3.2 Peptide Cancer Vaccine Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sellas
2.4.1 Business Overview
2.4.2 Peptide Cancer Vaccine Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Sellas Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Boston Biomedical
2.5.1 Business Overview
2.5.2 Peptide Cancer Vaccine Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Imugene
2.6.1 Business Overview
2.6.2 Peptide Cancer Vaccine Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Imugene Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 VAXON Biotech
2.7.1 Business Overview
2.7.2 Peptide Cancer Vaccine Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Generex Biotechnology
2.8.1 Business Overview
2.8.2 Peptide Cancer Vaccine Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 ISA Pharmaceuticals
2.9.1 Business Overview
2.9.2 Peptide Cancer Vaccine Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 OncoTherapy Science
2.10.1 Business Overview
2.10.2 Peptide Cancer Vaccine Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Immatics
2.11.1 Business Overview
2.11.2 Peptide Cancer Vaccine Type and Applications
2.11.2.1 Type 1
2.11.2.2 Type 2
2.11.3 Immatics Peptide Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 North America and Europe Peptide Cancer Vaccine Market Competition, by Manufacturer
3.1 North America and Europe Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
3.2 North America and Europe Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
3.2.1 North America and Europe Peptide Cancer Vaccine Revenue by Manufacturer (2016-2017)
3.2.2 North America and Europe Peptide Cancer Vaccine Revenue Market Share by Manufacturer (2016-2017)
3.3 North America and Europe Peptide Cancer Vaccine Price by Manufacturers (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Peptide Cancer Vaccine Manufacturer Market Share (2016-2017)
3.4.2 Top 5 Peptide Cancer Vaccine Manufacturer Market Share (2016-2017)
3.5 Market Competition Trend
4 North America and Europe Peptide Cancer Vaccine Market Analysis by Countries/Regions
4.1 North America and Europe Peptide Cancer Vaccine Sales Market Share by Countries/Regions
4.2 North America and Europe Peptide Cancer Vaccine Sales by Countries/Regions (2013-2018)
4.2.1 North America and Europe Peptide Cancer Vaccine Sales by Countries/Regions (2013-2018)
4.2.2 North America and Europe Peptide Cancer Vaccine Sales Market Share by Countries (2013-2018)
4.3 North America and Europe Peptide Cancer Vaccine Revenue (Value) by Countries (2013-2018)
4.3.1 North America and Europe Peptide Cancer Vaccine Revenue and Growth Rate (2013-2018)
4.3.2 North America and Europe Peptide Cancer Vaccine Revenue Market Share by Countries (2013-2018)
5 North America and Europe Market Segmentation Peptide Cancer Vaccine by Type
5.1 North America and Europe Peptide Cancer Vaccine Sales, Revenue and Market Share by Type (2013-2018)
5.1.1 North America and Europe Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
5.1.2 North America and Europe Peptide Cancer Vaccine Revenue and Market Share by Type (2013-2018)
6 North America and Europe Market Segmentation Peptide Cancer Vaccine by Application
6.1 North America and Europe Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
6.2 Breast Cancer Sales Growth (2013-2018)
6.3 Lung Cancer Sales Growth (2013-2018)
6.4 Melanoma Sales Growth (2013-2018)
6.5 Prostate Cancer Sales Growth (2013-2018)
6.6 Others Sales Growth (2013-2018)
7 United States Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
7.1 United States Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
7.2 United States Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
7.2.1 United States Peptide Cancer Vaccine Sales by Type (2013-2018)
7.2.2 United States Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
7.3 United States Peptide Cancer Vaccine Sales and Market Share by Application (2013-2018)
7.3.1 United States Peptide Cancer Vaccine Sales by Application (2013-2018)
7.3.2 United States Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
7.4 United States Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
7.4.1 United States Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
7.4.2 United States Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
7.5 United States Peptide Cancer Vaccine Export and Import (2013-2018)
8 United Kingdom Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
8.1 United Kingdom Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
8.2 United Kingdom Peptide Cancer Vaccine Sales and Market Share by Type (2016-2017)
8.2.1 United Kingdom Peptide Cancer Vaccine Sales by Type (2013-2018)
8.2.2 United Kingdom Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
8.3 United Kingdom Peptide Cancer Vaccine Sales and Market Share by Application (2013-2018)
8.3.1 United Kingdom Peptide Cancer Vaccine Sales by Application (2013-2018)
8.3.2 United Kingdom Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
8.4 United Kingdom Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
8.4.1 United Kingdom Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
8.4.2 United Kingdom Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
8.5 United Kingdom Peptide Cancer Vaccine Export and Import (2013-2018)
9 Canada Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
9.1 Canada Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
9.2 Canada Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
9.2.1 Canada Peptide Cancer Vaccine Sales by Type (2013-2018)
9.2.2 Canada Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
9.3 Canada "&Sheet1!$B$1&" Sales and Market Share by Application (2013-2018)"
9.3.1 Canada Peptide Cancer Vaccine Sales by Application (2013-2018)
9.3.2 Canada Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
9.4 Canada Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
9.4.1 Canada Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
9.4.2 Canada Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
9.5 Canada Peptide Cancer Vaccine Export and Import (2013-2018)
10 Germany Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
10.1 Germany Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
10.2 Germany Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
10.2.1 Germany Peptide Cancer Vaccine Sales by Type (2013-2018)
10.2.2 Germany Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
10.3 Germany Peptide Cancer Vaccine Sales and Market Share by Application (2013-2018)
10.3.1 Germany Peptide Cancer Vaccine Sales by Application (2013-2018)
10.3.2 Germany Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
10.4 Germany Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
10.4.1 Germany Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
10.4.2 Germany Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
10.5 Germany Peptide Cancer Vaccine Export and Import (2013-2018)
11 France Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
11.1 France Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
11.2 France Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
11.2.1 France Peptide Cancer Vaccine Sales by Type (2013-2018)
11.2.2 France Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
11.3 France "&Sheet1!$B$1&" Sales by Application (2013-2018)"
11.3.1 France Peptide Cancer Vaccine Sales by Application (2013-2018)
11.3.2 France Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
11.4 France Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
11.4.1 France Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
11.4.2 France Peptide Cancer Vaccine Revenue and Market Share by Manufacturer
11.5 France Peptide Cancer Vaccine Export and Import (2013-2018)
12 Italy Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
12.1 Italy Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
12.2 Italy Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
12.2.1 Italy Peptide Cancer Vaccine Sales by Type (2013-2018)
12.2.2 Italy Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
12.3 Italy Peptide Cancer Vaccine Sales and Market Share by Application (2013-2018)
12.3.1 Italy Peptide Cancer Vaccine Sales by Application (2013-2018)
12.3.2 Italy Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
12.4 Italy Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
12.4.1 Italy Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
12.4.2 Italy Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
12.5 Italy Peptide Cancer Vaccine Export and Import (2013-2018)
13 Spain Peptide Cancer Vaccine Sales, Revenue, by Type, Application and Manufacturers
13.1 Spain Peptide Cancer Vaccine Revenue, Sales and Growth Rate (2013-2018)
13.2 Spain Peptide Cancer Vaccine Sales and Market Share by Type (2013-2018)
13.2.1 Spain Peptide Cancer Vaccine Sales by Type (2013-2018)
13.2.2 Spain Peptide Cancer Vaccine Sales Market Share by Type (2013-2018)
13.3 Spain Peptide Cancer Vaccine Sales by Application (2013-2018)
13.3.1 Spain Peptide Cancer Vaccine Sales by Application (2013-2018)
13.3.2 Spain Peptide Cancer Vaccine Sales Market Share by Application (2013-2018)
13.4 Spain Peptide Cancer Vaccine Sales, Revenue and Market Share by Manufacturer (2016-2017)
13.4.1 Spain Peptide Cancer Vaccine Sales and Market Share by Manufacturer (2016-2017)
13.4.2 Spain Peptide Cancer Vaccine Revenue and Market Share by Manufacturer (2016-2017)
13.5 Spain Peptide Cancer Vaccine Export and Import (2013-2018)
14 Peptide Cancer Vaccine Market Forecast (2018-2023)
14.1 North America and Europe Peptide Cancer Vaccine Sales, Revenue and Growth Rate (2018-2023)
14.2 Peptide Cancer Vaccine Market Forecast by Countries/Regions (2018-2023)
14.2.1 United States Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.2.2 United Kingdom Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.2.3 Canada Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.2.4 Germany Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.2.5 France Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.2.6 Italy Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.2.7 Spain Peptide Cancer Vaccine Sales and Growth Rate Forecast (2018-2023)
14.3 Peptide Cancer Vaccine Market Forecast by Type (2018-2023)
14.3.1 North America and Europe Peptide Cancer Vaccine Sales Forecast by Type (2018-2023)
14.3.2 North America and Europe Peptide Cancer Vaccine Market Share Forecast by Type (2018-2023)
14.4 Peptide Cancer Vaccine Market Forecast by Application (2018-2023)
14.4.1 North America and Europe Peptide Cancer Vaccine Sales Forecast by Application (2018-2023)
14.4.2 North America and Europe Peptide Cancer Vaccine Market Share Forecast by Application (2018-2023)
15 Peptide Cancer Vaccine Manufacturing Cost Analysis
15.1 Peptide Cancer Vaccine Key Raw Materials Analysis
15.1.1 Key Raw Materials
15.1.2 Price Trend of Key Raw Materials
15.1.3 Key Suppliers of Raw Materials
15.1.4 Market Concentration Rate of Raw Materials
15.2 Proportion of Manufacturing Cost Structure
15.2.1 Raw Materials
15.2.2 Labor Cost
15.2.3 Manufacturing Expenses
15.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
16 Industrial Chain, Sourcing Strategy and Downstream Buyers
16.1 Peptide Cancer Vaccine Industrial Chain Analysis
16.2 Upstream Raw Materials Sourcing
16.3 Raw Materials Sources of Peptide Cancer Vaccine Major Manufacturers in 2017
16.4 Downstream Buyers
17 Sales Channel, Distributors, Traders and Dealers
17.1 Sales Channel
17.1.1 Direct Marketing
17.1.2 Indirect Marketing
17.1.3 Marketing Channel Future Trend
17.2 Distributors, Traders and Dealers
18 Research Findings and Conclusion
19 Appendix
19.1 Methodology
19.2 Data Source
North America and Europe Peptide Cancer Vaccine
North America and Europe Peptide Cancer Vaccine
×